Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERE-120 in Parkinson's Disease
NCT00985517Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Oct 2009
- Primary completion
- Nov 2014
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Neurturin gene therapy in Parkinson's disease (PD) (4 arms), sponsored by Sangamo Therapeutics. Primary endpoints: Number of Participants Who Received CERE-120 Treatment at 5 years and Change From Baseline in Motor Examination Part III Total Score in the 'Off' Condition at Month 24. Started Oct 2009; status: completed.
02
Drugs
Neurturin gene therapy
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00985517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985517.